Compare BioNTech SE - ADR (BNTX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs KB Financial Group, Inc. — how do they compare? BioNTech SE - ADR trades at $92.9 (market cap $23.31B), while KB Financial Group, Inc. trades at $117.39 (market cap $41.21B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays a 2.67% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KB | |
|---|---|---|
Market Cap | $23.31B | $41.21B |
Sector | Health | Financials |
52-Week High | $119.34 | $124.01 |
52-Week Low | $83.89 | $77.50 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
KB Financial Group (KB) trades at $118.00, down 2.26% today, with a bullish technical signal from moving averages. The stock shows strong fundamental performance with consistent earnings beats, 27.82% net income margin, and attractive valuation at P/E of 10.36 and P/B of 0.98. Recent news highlights momentum potential and diversification into non-banking segments, which now contribute 43% of earnings.
Outlook remains positive with earnings growth and shareholder returns as key catalysts, though risks include volatile operating environment and heavy investing cash outflows. Analyst consensus leans cautious with 67% hold ratings, suggesting potential upside requires continued execution on diversification and fee income growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
